Differential diagnosis of systemic scleroderma from the perspective of dermatologist
Authors:
O. Kodet 1,2,3; J. Štork 1
Authors place of work:
Dermatovenerologická klinika 1. LF UK a VFN, Praha
1; Anatomický ústav 1. LF UK, Praha
2; BIOCEV – Biotechnologické a biomedicínské centrum Akademie věd a Univerzity Karlovy, Vestec u Prahy
3
Published in the journal:
Čes. Revmatol., 28, 2020, No. 3, p. 169-181.
Category:
Review Article
Summary
Conditions assessed in the differential diagnosis of systemic sclerosis or scleroderma (SSc) are associated with some degree of skin fibrosis. These diseases are sometimes referred to as scleroderma-like syndromes and they are diverse and completely different etiology and often unclear pathogenesis. The different and relatively various clinical characteristics of each of these diseases may help to differentiate these conditions from systemic sclerosis. Histopathological examination with clinical-pathological correlation is, in some cases, necessary to make a definitive diagnosis and to select an appropriate therapeutic approach. This summary provides a brief overview of diseases that, because of their skin involvement, are the most common parts of the differential diagnosis of SSc. The differential diagnosis includes generalized morphea (localized scleroderma), eosinophilic fasciitis, nephrogenic systemic fibrosis, stiff skin syndrome, scleromyxedema, scleredema adultorum, diabetic cheiroarthropathy and systemic amyloidosis. The interdisciplinary approach, and the cooperation of rheumatology and dermatology, is an irreplaceable differential diagnostic procedure for the correct diagnosis of these diseases.
Keywords:
scleromyxedema – generalized localized scleroderma – eosinophilic fasciitis – nephrogenic systemic fibrosis – scleredema
Zdroje
1. Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol 2018; 32: 223–240.
2. Nikpour M, Stevens WM, Herrick AL, Proudman SM. Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 857–869.
3. Sehgal VN, Srivastava G, Aggarwal AK, Behl PN, Choudhary M, Bajaj P. Localized scleroderma/morphea. Int J Dermatol 2002; 41: 467–475.
4. Gabrielli A, Avvedimento E V, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989–2003.
5. Fett N, Werth VP. Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64: 217–228.
6. Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma. JDDG – J Ger Soc Dermatology 2016; 14: 199–216.
7. Peterson LS, Nelson AM, Su WPD, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol 1997; 24: 73–80.
8. Kreuter A, Wischnewski J, Terras S, Altmeyer P, Stücker M, Gambichler T. Coexistence of lichen sclerosus and morphea: A retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol 2012; 67: 1157–1162.
9. Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford) 2009; 48: 213–221.
10. Yamane K, Ihn H, Kubo M, et al. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol 2000; 42: 64–69.
11. Marzano A V., Menni S, Parodi A, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations of 239 cases. Eur J Dermatology 2003; 13: 171–176.
12. Sato T, Goto M, Takeo N, Hatano Y. Case of generalized morphea with the manifestation of diffuse systemic cutaneous sclerosis without sclerodactyly. J Dermatol 2018; 45: e100–101.
13. Adamska U, Slinko A, Białecka A, Męcińska-Jundziłł K, Adamski P, Czajkowski R. Unilateral generalized morphea: a case report and literature review. Postep dermatologii i Alergol 2018; 35: 425–428.
14. Cantisani C, Miraglia E, Richetta AG, Mattozzi C, Calvieri S. Generalized morphea successfully treated with tacrolimus 0.1% ointment. J Drugs Dermatol 2013; 12: 14–15.
15. Walker D, Susa JS, Currimbhoy S, Jacobe H. Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort V. J Am Acad Dermatol 2017; 76: 1124–1130.
16. Spielmann L, Arnaud L, Severac F, et al. Population-based prevalence of eosinophilic fasciitis (Shulman syndrome): a capture-recapture study. Br J Dermatol 2018; 179: 516–517.
17. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988; 17: 221–231.
18. Bielsa Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr 2013; 104: 654–666.
19. Liu Y, Zeng Y, Xie Y, et al. Eosinophilic fasciitis associated with myositis: Report of four cases and review of the literature. Australas J Dermatol 2019; 60: e227–231.
20. Onajin O, Wieland CN, Peters MS, Lohse CM, Lehman JS. Clinicopathologic and immunophenotypic features of eosinophilic fasciitis and morphea profunda: A comparative study of 27 cases. J Am Acad Dermatol 2018; 78: 121–128.
21. Walker D, Susa JS, Currimbhoy S, Jacobe H. Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort V. J Am Acad Dermatol 2017; 76: 1124–1130.
22. Baumann F, Brühlmann P, Andreisek G, Michel BA, Marincek B, Weishaupt D. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. Am J Roentgenol 2005; 184: 169–174.
23. Haustein U-F. Scleroderma and pseudo-scleroderma: uncommon presentations. Clin Dermatol 2005; 23: 480–490.
24. Foti R, Leonardi R, Rondinone R, et al. Scleroderma-like disorders. Autoimmun Rev 2008; 7: 331–339.
25. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol 2017; 53: 306–336.
26. Kelsey CE, Torok KS. The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population. J Am Acad Dermatol 2013; 69: 214–220.
27. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011; 65: 925–941.
28. Caca-Biljanovska NG, Vlckova-Laskoska MT, Dervendi D V, Pesic NP, Laskoski DS. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 1999; 455: 299–304.
29. Stefanaki C, Stefanaki K, Kontochristopoulos G, et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 2008; 35: 712–718.
30. Dytoc M, Wat H, Cheung-Lee M, Sawyer D, Ackerman T, Fiorillo L. Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial. J Cutan Med Surg 2015; 19: 132–139.
31. Kroft EBM, Berkhof NJG, van de Kerkhof PCM, Gerritsen RMJP, de Jong EMGJ. Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review. J Am Acad Dermatol 2008; 59: 1017–1030.
32. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005; 141: 847–852.
33. Mazori DR, Femia AN, Vleugels RA. Eosinophilic Fasciitis: an updated review on diagnosis and treatment. Curr Rheumatol Rep 2017; 19: 74.
34. Endrikat J, Dohanish S, Schleyer N, Schwenke S, Agarwal S, Balzer T. 10 years of nephrogenic systemic fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016. Invest Radiol 2018; 53: 541–550.
35. Smorodinsky E, Ansdell DS, Foster ZW, et al. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015; 41: 1259–1267.
36. Bruce R, Wentland AL, Haemel AK, et al. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients with Renal Insufficiency Compared with Gadodiamide. Invest Radiol 2016; 51: 701–705.
37. Thomsen HS. Nephrogenic systemic fibrosis: A serious adverse reaction to gadolinium-1997-2006-2016. Part 2. Acta Radiol 2016; 57: 643–648.
38. Thomsen HS. Nephrogenic systemic fibrosis: A serious adverse reaction to gadolinium-1997-2006-2016. Part 1. Acta Radiol 2016; 57: 515–520.
39. Liu T, McCalmont TH, Frieden IJ, Williams ML, Connolly MK, Gilliam AE. The stiff skin syndrome: Case series, differential diagnosis of the stiff skin phenotype, and review of the literature. Arch Dermatol 2008; 144: 1351–1359.
40. Deng X, Chen F, Song Z, et al. Four new cases of stiff skin syndrome with unusual presentations. J Eur Acad Dermatol Venereol 2016; 30: 163–165.
41. Geng S, Lei X, Toyohara JP, Zhan P, Wang J, Tan S. Stiff skin syndrome. J Eur Acad Dermatol Venereol 2006; 20: 729–732.
42. Guiducci S, Distler JHW, Milia AF, et al. Stiff skin syndrome: Evidence for an inflammation-independent fibrosis? Rheumatology (Oxford) 2009; 48: 849–852.
43. Victor V, Margareat RM. Plasma cell myeloma masquerading as scleromyxedema. Indian Dermatol Online J 2019; 10: 50–53.
44. Aoki M, Matsushita S, Kawai K, Kanekura T. Scleromyxedema clinically resembling to scleroderma. Indian J Dermatol 2016; 61: 127.
45. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44: 273–281.
46. Nofal A, Amer H, Nofal E. Scleromyxedema without paraproteinemia. Int J Dermatol 2016; 55: e418–419.
47. Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatology Venereol 2017; 31: 45–52.
48. Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol 2001; 23: 257–267.
49. Guarneri A, Cioni M, Rongioletti F. High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatology Venereol 2017; 31: 1157–1160.
50. Saniee S, Davarnia G. Scleromyxedema without paraproteinemia: Treatment with thalidomide and prednisolone. Case Rep Dermatol 2016; 8: 327–332.
51. Cole GW, Headley J, Skowsky R. Scleredema diabeticorum: A common and distinct cutaneous manifestation of diabetes mellitus. Diabetes Care 1983; 6: 189–192.
52. Sattar MA, Diab S, Sugathan TN, Sivanandasingham P, Fenech FF. Scleroedema diabeticorum: a minor but often unrecognized complication of diabetes mellitus. Diabet Med 1988; 5: 465–468.
53. Meguerditchian C, Jacquet P, Béliard S, et al. Scleredema adultorum of Buschke: An under recognized skin complication of diabetes. Diabetes Metab 2006; 32: 481–484.
54. Miguel D, Schliemann S, Elsner P. Treatment of scleroedema adultorum buschke: A systematic review. Acta Derm Venereol 2018; 98: 305–309.
55. Kreuter A. Scleredema adultorum: Clinical presentation, diagnostic workup, differential diagnosis, treatment option. Hautarzt 2018; 69: 908–915.
56. Raboudi A, Litaiem N. Scleredema (Buschke Disease, Scleredema of Buschke, Scleredema Adultorum). In: StatPearls. Treasure Island (FL): StatPearls Publishing 2020.
57. Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 2006; 35: 355–359.
58. Jelinek JE. The skin in diabetes. Diabet Med 1993; 10: 201–213.
59. Arkkila PE, Kantola IM, Viikari JS. Limited joint mobility in type 1 diabetic patients: correlation to other diabetic complications. J Intern Med 1994; 236: 215–223.
60. Ramchurn N, Mashamba C, Leitch E, et al. Upper limb musculoskeletal abnormalities and poor metabolic control in diabetes. Eur J Intern Med 2009; 20: 718–721.
61. Cherqaoui R, McKenzie S, Nunlee-Bland G. Diabetic cheiroarthropathy: a case report and review of the literature. Case Rep Endocrinol 2013; 2013: 257028.
62. Hider SL, Roy DK, Augustine T, Parrott N, Bruce IN. Resolution of diabetic cheiroarthropathy after pancreatic transplantation. Diabetes Care 2004; 27: 2279–2280.
63. Palladini G, Merlini G. Systemic amyloidoses: what an internist should know. Eur J Intern Med 2013; 24: 729–739.
64. Schreml S, Szeimies R-M, Vogt T, Landthaler M, Schroeder J, Babilas P. Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. Eur J Dermatol 2010; 20:152–160.
65. Weidner T, Illing T, Elsner P. Primary localized cutaneous amyloidosis: a systematic treatment review. Am J Clin Dermatol 2017; 18: 629–642.
66. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016; 387: 2641–2654.
67. Nilsson KPR, Ikenberg K, Aslund A, et al. Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. Am J Pathol 2010; 176: 563–574.
68. Dember LM, Madias NE, Harrington JT, Perrone RD, Levey AS, Kausz A. Emerging treatment approaches for the systemic amyloidoses. Kidney Int 2005; 68: 1377–1390.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2020 Číslo 3
Najčítanejšie v tomto čísle
- Current impact of seronegative rheumatoid arthritis
- The role of viruses in the development of autoimmune diseases
- Validation of Czech versions of questionnaires assessing fatigue and physical acti- vity in patients with rheumatic diseases: Fatigue Impact Scale (FIS), Multidimensional Assessment of Fatigue Scale (MAF), Human Activity Profile (HAP)
- Diet in gout – should we reduce the intake of purines?